CliffBio
small molecule

EDARBYCLOR

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

Loss of exclusivityJuly 2031latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameEDARBYCLOR
Active ingredientAZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE
StrengthEQ 40MG MEDOXOMIL;12.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2011
Marketing statusRX

Listed patents

PatentExpiresType
9387249July 2031use U-3
9169238February 2030product
9066936March 2028product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EDARBYCLOR patent cliff — loss of exclusivity July 2031 | CliffBio